{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:22:16Z","timestamp":1789593736139,"version":"build-2803163510"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007816","name":"Alcon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007816","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jcrsjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.jcrs.2018.08.039","type":"journal-article","created":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T22:51:09Z","timestamp":1544223069000},"page":"174-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Tolerability and toxicity of topically applied nepafenac 0.3% compared with generic ketorolac 0.5%"],"prefix":"10.1097","volume":"45","author":[{"given":"John","family":"Hovanesian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210210","first-page":"249","article-title":"Cataract blindness - challenges for the 21st century.","volume":"79","author":"Brian","year":"2001","journal-title":"Bull World Health Organ"},{"key":"R2-10-20210210","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1076\/opep.11.2.67.28158","article-title":"2002 global update of available data on visual impairment: a compilation of population-based prevalence studies.","volume":"11","author":"Pascolini","year":"2004","journal-title":"Ophthalmic Epidemiol"},{"key":"R3-10-20210210","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1167\/iovs.12-10657","article-title":"Cataract conversion assessment using lens opacity classification system III and Wisconsin cataract grading system.","volume":"54","author":"Wong","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R4-10-20210210","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2147\/OPTH.S23381","article-title":"Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction.","volume":"6","author":"Carreno","year":"2012","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"R5-10-20210210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00004397-200201000-00003","article-title":"Topical nonsteroidal anti-inflammatory drugs in ophthalmology.","volume":"42","author":"Flach","year":"2002","journal-title":"Int Ophthalmol Clin"},{"key":"R7-10-20210210","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2147\/OPTH.S31902","article-title":"Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy.","volume":"6","author":"Singh","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"R8-10-20210210","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2147\/OPTH.S4806","article-title":"Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution.","volume":"3","author":"Cho","year":"2009","journal-title":"Clin Ophthalmol"},{"key":"R9-10-20210210","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1185\/030079906X112471","article-title":"Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium.","volume":"22","author":"Waterbury","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"R10-10-20210210","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.iio.0000212134.83513.11","article-title":"Global experience with Xibrom (bromfenac ophthalmic solution) 0.09: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug.","volume":"46","author":"Donnenfeld","year":"2006","journal-title":"Int Ophthalmol Clin"},{"key":"R11-10-20210210","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.ophtha.2011.04.035","article-title":", for the Bromfenac Ophthalmic Solution (Bromday) Once Daily Study Group. Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain.","volume":"118","author":"Henderson","year":"2011","journal-title":"Ophthalmology"},{"key":"R12-10-20210210","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1185\/03007995.2011.597663","article-title":", Bromfenac Ophthalmic Solution Once Daily (Bromday) Study Group. Once daily dosing of bromfenac ophthalmic solution 0.09 for postoperative ocular inflammation and pain.","volume":"27","author":"Silverstein","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"R13-10-20210210","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/01.iio.0000212129.53019.49","article-title":"Nepafenac: a unique nonsteroidal prodrug.","volume":"46","author":"Lane","year":"2006","journal-title":"Int Ophthalmol Clin"},{"key":"R14-10-20210210","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00417-017-3599-8","article-title":"The comparative efficacy and safety of topical non-steroidal anti-inflammatory drugs for the treatment of anterior chamber inflammation after cataract surgery: a systematic review and network meta-analysis.","volume":"255","author":"Duan","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R15-10-20210210","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1023\/A:1026024409826","article-title":"Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac.","volume":"27","author":"Kapin","year":"2003","journal-title":"Inflammation"},{"key":"R16-10-20210210","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1023\/A:1007049015148","article-title":"Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy.","volume":"24","author":"Gamache","year":"2000","journal-title":"Inflammation"},{"key":"R17-10-20210210","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jcrs.2016.06.006","article-title":", for the ASCRS Cataract Clinical Committee and the American Glaucoma Society. Cataract surgery and nonsteroidal antiinflammatory drugs.","volume":"42","author":"Hoffman","year":"2016","journal-title":"J Cataract Refract Surg"},{"key":"R18-10-20210210","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/OPX.0b013e318157ac9e","article-title":"The development of validated bulbar redness grading scales.","volume":"84","author":"Schulze","year":"2007","journal-title":"Optom Vis Sci"},{"key":"R19-10-20210210","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.","volume":"140","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R20-10-20210210","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/00003226-200310000-00008","article-title":"Grading of corneal and conjunctival staining in the context of other dry eye tests.","volume":"22","author":"Bron","year":"2003","journal-title":"Cornea"},{"key":"R21-10-20210210","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1477-7525-9-111","article-title":", for the impact of dry eye on everyday life (IDEEL) Study Group. Development and validation of the Impact of Dry Eye on Everyday Life (IDEEL) questionnaire, a patient-reported outcomes (PRO) measure for the assessment of the burden of dry eye on patients.","volume":"9","author":"Abetz","year":"2011","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"R22-10-20210210","doi-asserted-by":"crossref","first-page":"e0173254","DOI":"10.1371\/journal.pone.0173254","article-title":"Comparison of the efficacy and patients tolerability of Nepafenac and Ketorolac in the treatment of ocular inflammation following cataract surgery: a meta-analysis of randomized controlled trials.","volume":"12","author":"Zhao","year":"2017","journal-title":"PLoS One"},{"key":"R23-10-20210210","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.ophtha.2014.04.035","article-title":"Post-cataract prevention of inflammation and macula edema by steroid and nonsteroidal anti-inflammatory eye drops; a systematic review.","volume":"121","author":"Kessel","year":"2014","journal-title":"Ophthalmology"},{"issue":"12","key":"R25-10-20210210","first-page":"NC05","article-title":"To study the efficacy of difluprednate ophthalmic emulsion and prednisolone acetate ophthalmic suspension on post-operative inflammation in cataract surgery.","volume":"10","author":"Garg","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"R26-10-20210210","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/eye.2016.132","article-title":"Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study.","volume":"30","author":"Wilson","year":"2016","journal-title":"Eye"},{"key":"R27-10-20210210","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jfo.2014.06.005","article-title":"Traitement du glaucome, conservateurs et surface oculair Glaucoma medications, preservatives and the ocular surface.","volume":"37","author":"Aptel","year":"2014","journal-title":"J Fr Ophtalmol"},{"key":"R28-10-20210210","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1089\/jop.2013.0216","article-title":", for the Beta-Blocker Study Group. Ocular surface changes in glaucomatous patients treated with and without preservatives beta-blockers.","volume":"30","author":"Iester","year":"2014","journal-title":"J Ocul Pharmacol Ther"},{"key":"R29-10-20210210","first-page":"2","article-title":"Preservatives from the eye drops and the ocular surface.","volume":"59","author":"Coroi","year":"2015","journal-title":"Rom J Ophthalmol"},{"key":"R30-10-20210210","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1167\/iovs.14-14548","article-title":"The effect of preservatives and antiglaucoma treatments on the ocular surface of mice with dry eye.","volume":"55","author":"Barabino","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R32-10-20210210","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2147\/OPTH.S120159","article-title":", on behalf of the PHACO Study Group. The Prospective Health Assessment of Cataract Patients Ocular Surface (PHACO) study: the effect of dry eye.","volume":"11","author":"Trattler","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"R33-10-20210210","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.sjopt.2014.06.013","article-title":"Cataract surgery in patients with ocular surface disease: an update in clinical diagnosis and treatment.","volume":"28","author":"Afsharkhamseh","year":"2014","journal-title":"Saudi J Ophthalmol"},{"key":"R34-10-20210210","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/ICU.0b013e32834d90b7","article-title":"Cataract surgery in the face of ocular surface disease.","volume":"23","author":"Movahedan","year":"2012","journal-title":"Curr Opin Ophthalmol"},{"key":"R35-10-20210210","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/jop.2006.22.251","article-title":"Evaluation of 0.4 ketorolac tromethamine ophthalmic solution versus 0.5 ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantation.","volume":"22","author":"Sandoval","year":"2006","journal-title":"J Ocul Pharmacol Ther"},{"key":"R36-10-20210210","first-page":"367","article-title":"A review of the use of ketorolac tromethamine 0.4 in the treatment of post-surgical inflammation following cataract and refractive surgery.","volume":"1","author":"Sandoval","year":"2007","journal-title":"Clin Ophthalmol"},{"issue":"suppl","key":"R37-10-20210210","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.4103\/0301-4738.73693","article-title":"Compliance and adherence in glaucoma management.","volume":"59","author":"Robin","year":"2011","journal-title":"Indian J Ophthalmol"},{"key":"R38-10-20210210","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ajo.2009.04.023","article-title":"Corneal epithelial opacity in dysfunctional tear syndrome.","volume":"148","author":"Chen","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R39-10-20210210","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1167\/iovs.17-21894","article-title":"The effect of ocular surface regularity on contrast sensitivity and straylight in dry eye.","volume":"58","author":"Koh","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Journal of Cataract and Refractive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0886335018308629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0886335018308629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1016\/j.jcrs.2018.08.039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T18:34:43Z","timestamp":1623782083000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/02158034-201902000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jcrs.2018.08.039","relation":{},"ISSN":["0886-3350"],"issn-type":[{"value":"0886-3350","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tolerability and toxicity of topically applied nepafenac 0.3% compared with generic ketorolac 0.5%","name":"articletitle","label":"Article Title"},{"value":"Journal of Cataract & Refractive Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcrs.2018.08.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 ASCRS and ESCRS Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}